Lung cancer trials in Austria

In Austria 58 Also abroad 2733

58 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Where
Feldkirch, Innsbruck, Krems An Der Donau, Vienna
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00
Phase 1Taking people
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Where
Linz
Age
18 years and over
People
554 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT04886804 · EU 2024-511246-39-00
Phase 3Taking people
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Where
Feldkirch, Innsbruck, Krems An Der Donau, Linz, Vienna, Wels
Age
18 years and over
People
675 worldwide
Run by
AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00
Phase 3Taking people
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
Where
Vienna
Age
18 years and over
People
390 worldwide
Run by
ETOP IBCSG Partners Foundation
See details and how to joinNCT06931717 · EU 2024-519901-36-00
Phase 3Taking people
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Where
Graz, Linz, Vienna, Wels
Age
18 years and over
People
630 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00
Phase 2/3Taking people
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Where
Feldkirch, Linz, Vienna
Age
18 years and over
People
590 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00
Phase 3Taking people
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Where
Feldkirch, Linz, St. Poelten
Age
18 years and over
People
750 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00
Phase 3Taking people
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
Where
Salzburg, Vienna
Age
18 years and over
People
263 worldwide
Run by
Zai Lab (US) LLC
See details and how to join2025-522818-23-00 · EU 2025-522818-23-00
Phase 1/2Taking people
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Where
St. Poelten, Vienna
Age
18 years and over
People
616 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06162221 · EU 2025-521147-21-00
No phaseTaking people
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
Where
Graz
Age
18 years and over
People
600 worldwide
Run by
European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04790253
Phase 3Taking people
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Where
Salzburg, Vienna
Age
18 years and over
People
480 worldwide
Run by
Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07218146
Phase 2/3Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Vienna
Age
18 years and over
People
490 worldwide
Run by
AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Graz, Vienna
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 3Taking people
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Where
Innsbruck, Vienna
Age
18 years and over
People
450 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00
Phase 3Taking people
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Where
Graz, Linz, Vienna
Age
18 years and over
People
714 worldwide
Run by
Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00
Phase 3Taking people
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Where
Innsbruck, Krems An Der Donau, Linz
Age
18 years and over
People
531 worldwide
Run by
AbbVie
See details and how to joinNCT07365241 · EU 2025-523819-11-00
Phase 2Taking people
Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis
Where
Graz, Vienna
Age
18 years and over
People
20 worldwide
Run by
MedSIR
See details and how to joinNCT06315010 · EU 2023-508112-35-00
Phase 3Taking people
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
Where
Graz, Krems An Der Donau
Age
18 years and over
People
156 worldwide
Run by
Amgen Inc.
See details and how to join2024-520050-38-00 · EU 2024-520050-38-00
Phase 3Taking people
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Where
Feldkirch, Krems An Der Donau, Linz, Vienna
Age
18 years and over
People
540 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06203210 · EU 2023-509628-16-00
No phaseTaking people
EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER
Where
Graz
Age
18 years to 75 years
People
50
Run by
Medical University of Graz
See details and how to joinNCT07267000
Phase 2Not yet taking people in Austria
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
Where
Linz, Vienna
Age
18 years and over
People
158 worldwide
Run by
European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT07234877 · EU 2025-522985-60-00
No phaseTaking people
Confocal Laser Endomicroscopy VERification
Where
Vienna
Age
18 years and over
People
208 worldwide
Run by
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
See details and how to joinNCT06079970
No phaseTaking people
Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab
Where
Sankt Pölten
Age
18 years and over
People
240 worldwide
Run by
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
See details and how to joinNCT07510724
No phaseTaking people
Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer
Where
Krems
Age
18 years and over
People
10
Run by
Karl Landsteiner University of Health Sciences
See details and how to joinNCT07423169
No phaseTaking people
Discrimination of N2a and N2b by EBUS-TBNA: is a Change of the Needle Necessary?
Where
Vienna
Age
18 years and over
People
30
Run by
University of Vienna
See details and how to joinNCT07418450